These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1405603)

  • 61. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
    Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.
    Habtetsion T; Ding ZC; Pi W; Li T; Lu C; Chen T; Xi C; Spartz H; Liu K; Hao Z; Mivechi N; Huo Y; Blazar BR; Munn DH; Zhou G
    Cell Metab; 2018 Aug; 28(2):228-242.e6. PubMed ID: 29887396
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
    Aruga A; Aruga E; Tanigawa K; Bishop DK; Sondak VK; Chang AE
    J Immunol; 1997 Jul; 159(2):664-73. PubMed ID: 9218581
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enhancing effect of interleukin 1 alpha administration on antitumor effector T-cell development.
    Sondak VK; Tuck MK; Shu S; Yoshizawa H; Chang AE
    Arch Surg; 1991 Dec; 126(12):1503-8; discussion 1508-9. PubMed ID: 1842180
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumor reactivity of immune T cells in short-term culture.
    Krauss JC; Stein JM; Shu S
    Cancer Immunol Immunother; 1996 Dec; 43(4):231-9. PubMed ID: 9003469
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma.
    Maglioco A; Machuca D; Mundiñano J; Cabrera G; Camicia G; Bruzzo J; Camerano G; Costa H; Ruggiero RA; Dran GI
    Cancer Immunol Immunother; 2011 Mar; 60(3):389-99. PubMed ID: 21153814
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
    Weber JS; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5818-24. PubMed ID: 3139284
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
    Cameron RB; McIntosh JK; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
    Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
    J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.
    Tao H; Lu L; Xia Y; Dai F; Wang Y; Bao Y; Lundy SK; Ito F; Pan Q; Zhang X; Zheng F; Shu G; Fang B; Jiang J; Xia J; Huang S; Li Q; Chang AE
    Eur J Immunol; 2015 Apr; 45(4):999-1009. PubMed ID: 25545618
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
    Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
    J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
    Young MR; Wright MA
    Cancer Res; 1992 Nov; 52(22):6335-40. PubMed ID: 1423279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.